Document Detail

Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
MedLine Citation:
PMID:  21063395     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVES: Early viral kinetics accurately predicts sustained virological response (SVR) in genotype 1 patients with hepatitis C virus (HCV) undergoing therapy with pegylated interferon (PEG) and ribavirin (RBV). No baseline factor has a stronger predictive role. Early identification of patients unlikely to respond is equally important, allowing early treatment modification or discontinuation. The aim of this study was to determine whether 4-week null response (eNR) correlates directly with 12-week null response and inversely with SVR.
METHODS: A retrospective analysis of HCV patients treated at our institution was done. Patients were classified based on a 4-week viral log decline compared with baseline: <1 log, ≥1 log, <2 log, ≥2 log, <3 log, ≥3 log without rapid virological response (RVR) and with RVR. eNR was defined as less than a 1 log change from baseline.
RESULTS: A total of 159 patients had quantitative HCV-RNA PCR at treatment week 4, of whom 24% (38) experienced eNR. In all, 22 (58%) of the eNR patients were African American, 58% male, 32% cirrhotic, average age 53 years (range 36-71), 89% (33) genotype 1, and average baseline viral load was 5.9261 log (range 3.1492-7.3025). On-treatment response demonstrated failure to attain early virological response (EVR; 2-log decline at week 12) in 50% (19) and partial EVR (pEVR) in 39% (15). Three (8%) patients with eNR achieved SVR. In our patient population, eNR had 92% negative predictive value (confidence interval 83.5-100%) for SVR and was the strongest single predictor for treatment failure, including the baseline factors genotype and viral load.
CONCLUSIONS: eNR is strongly associated with null response or pEVR and accurately predicts failure to attain SVR. Consideration should be made to discontinue or modify therapy in patients with eNR who receive the appropriate weight-based PEG/RBV.
Nancy Reau; Rohit Satoskar; Helen Te; Amanda Devoss; Carolyn Elsen; Gautham Reddy; Smruti Mohanty; Donald Jensen
Related Documents :
11742435 - Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical pra...
12715315 - Once-a-day highly active antiretroviral therapy: a systematic review.
18641035 - Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is ...
7840915 - Future treatment strategies in hiv infection.
19808455 - Atrial fibrillation ablation strategies for paroxysmal patients: randomized comparison ...
2559485 - Thrombin-antithrombin iii complexes in the prediction of deep vein thrombosis following...
Publication Detail:
Type:  Journal Article     Date:  2010-11-09
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  106     ISSN:  1572-0241     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-03-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  452-8     Citation Subset:  IM    
University of Chicago Medical Center, Center for Liver Disease, Chicago, Illinois, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Validation of a bowel function diary for assessing opioid-induced constipation.
Next Document:  A patient with tracheoesophageal fistula and esophageal cancer after radiotherapy.